Association between treatment toxicity and outcomes in oncology clinical trials, Annals of Oncology, vol.25, issue.11, pp.2284-2289, 2014. ,
Information theory and an extension of the maximum likelihood principle, International Symposium on Information Theory, pp.267-281, 1973. ,
Flexible univariate and multivariate models based on hidden truncation, Journal of Statistical Planning and Inference, vol.139, issue.11, pp.3741-3749, 2009. ,
The skew-normal distribution and related multivariate families (with discussion), Scandinavian Journal of Statistics, vol.32, pp.159-200, 2005. ,
Cancer phase i clinical trials: efficient dose escalation with overdose control, Stat Med, vol.17, issue.10, pp.1103-1120, 1998. ,
Joint modelling of repeated measurements and time-to-event outcomes: Flexible model specification and exact likelihood inference, Journal of the Royal Statistical Society. Series B: Statistical Methodology, vol.77, issue.1, pp.131-148, 2015. ,
A Bayesian approach to jointly modeling toxicity and biomarker expression in a phase I/II dose-finding trial, Biometrics, vol.61, issue.2, pp.344-354, 2005. ,
Bayesian adaptive methods for clinical trials, 2010. ,
Endpoints and other considerations in phase I studies of targeted anticancer therapy: Recommendations from the task force on Methodology for the Development of Innovative Cancer Therapies (MDICT), European Journal of Cancer, vol.44, issue.1, pp.19-24, 2008. ,
A Bayesian Dose-finding Design for Oncology Clinical Trials of Combinational Biological Agents, Journal of the Royal Statistical Society. Series C, Applied statistics, vol.63, issue.1, pp.159-173, 2014. ,
Management of immune checkpoint blockade dysimmune toxicities: A collaborative position paper, Annals of Oncology, vol.27, issue.4, pp.559-574, 2016. ,
, , 2018.
, Molecular testing for BRAF mutations to inform melanoma treatment decisions: A move toward precision medicine, Modern Pathology, vol.31, issue.1, pp.24-38
Dose finding by the continual reassessment method, Biostatistics Series, 2011. ,
Sequential designs for phase i clinical trials with late-onset toxicities, Biometrics, vol.56, issue.4, pp.1177-1182, 2000. ,
A simple technique to evaluate model sensitivity in the continual reassessment method, Biometrics, vol.58, pp.671-674, 2002. ,
Handbook of statistics in clinical oncology, 2012. ,
Evaluating the performance of copula models in phase I-II clinical trials under model misspecification, BMC Medical Research Methodology, vol.14, pp.1471-2288, 2014. ,
Evaluation of statistical designs in phase i expansion cohorts: The Dana-Farber/Harvard cancer center experience, Journal of the National Cancer Institute, issue.7, p.106, 2014. ,
Dose-finding designs in pediatric phase I clinical trials: Comparison by simulations in a realistic timeline framework, Contemporary Clinical Trials, vol.33, issue.4, pp.657-665, 2012. ,
Nonparametric estimates of standard error: The jackknife, the bootstrap and other methods, Biometrika, vol.68, issue.3, pp.589-599, 1981. ,
Phase I cancer clinical trials: A practical guide, 2015. ,
, Draft Guideline on the evaluation of anticancer medicinal products in man, European Medicines Agency, 2016.
Simultaneously modelling censored survival data and repeatedly measured covariates: A Gibbs sampling approach, Statistics in Medicine, vol.15, issue.15, pp.1663-1685, 1996. ,
Joint modelling of longitudinal measurements and event time data, Biostatistics, vol.1, pp.465-480, 2000. ,
An adaptive dose-finding approach for correlated bivariate binary and continuous outcomes in phase I oncology trials, Statistics in Medicine, vol.31, issue.6, pp.516-532, 2012. ,
Dose escalation trial designs based on a molecularly targeted endpoint, Statistics in Medicine, vol.24, issue.14, pp.2171-2181, 2005. ,
The impact of non-drug-related toxicities on the estimation of the maximum tolerated dose in phase i trials, Clinical Cancer Research, vol.18, issue.19, pp.5179-5187, 2012. ,
Basic concepts and methods for joint models of longitudinal and survival data, Journal of Clinical Oncology, vol.28, issue.16, pp.2796-2801, 2010. ,
Clinical safety data management: Definitions and standards for expedited reporting E2A, 1994. ,
Dose finding for continuous and ordinal outcomes with a monotone objective function: A unified approach, Biometrics, vol.65, issue.1, pp.1-19, 2009. ,
Continuous toxicity monitoring in phase II trials in oncology, Biometrics, vol.61, issue.2, pp.540-545, 2005. ,
Dose-finding when the target dose is on a plateau of a dose-response curve: Comparison of fully sequential designs, Pharmaceutical Statistics, vol.12, issue.5, pp.309-314, 2013. ,
Measuring response in solid tumors: Unidimensional versus bidimensional measurement, Journal of the National Cancer Institute, vol.91, issue.6, pp.523-528, 1999. ,
Predictive value of phase i trials for safety in later trials and final approved dose: Analysis of 61 approved cancer drugs, Clinical Cancer Research, vol.20, issue.2, pp.281-288, 2014. ,
Modified toxicity probability interval design: a safer and more reliable method than the 3 + 3 design for practical phase i trials, J Clin Oncol, vol.31, issue.14, pp.1785-1791, 2013. ,
Using data augmentation to facilitate conduct of phase I-II clinical trials with delayed outcomes, Journal of the American Statistical Association, vol.109, issue.506, pp.525-536, 2014. ,
A Bayesian adaptive phase I-II clinical trial for evaluating efficacy and toxicity with delayed outcomes, Clinical Trials, vol.11, issue.1, pp.38-48, 2014. ,
Drug development in oncology : classical cytotoxics and molecularly targeted agents, vol.62, pp.15-26, 2006. ,
Joint modeling of survival and longitudinal non-survival data: Current methods and issues. Report of the DIA Bayesian joint modeling working group, Statistics in Medicine, vol.34, issue.14, pp.2181-2195, 2015. ,
URL : https://hal.archives-ouvertes.fr/ineris-01855169
Current challenges for the early clinical development of anticancer drugs in the era of molecularly targeted agents, Targeted Oncology, vol.5, issue.1, pp.65-72, 2010. ,
Choice of starting dose for molecularly targeted agents evaluated in first-in-human phase I cancer clinical trials, Journal of Clinical Oncology, vol.28, issue.8, pp.1401-1407, 2010. ,
On the analysis of discrete time competing risks data, Biometrics, 2018. ,
Vemurafenib and BRAF inhibition: A new class of treatment for metastatic melanoma, Clinical Cancer Research, vol.18, issue.1, pp.9-14, 2012. ,
Advances in joint modelling: A review of recent developments with application to the survival of end stage renal disease patients, International Statistical Review, vol.81, issue.2, pp.249-269, 2013. ,
, Informative Visit Processes, vol.72, pp.1315-1324, 2016.
Model-guided determination of maximum tolerated dose in Phase I clinical trials: Evidence for increased precision, J Nat Can Inst, vol.85, issue.3, pp.217-223, 1993. ,
Critical aspects of the bayesian approach to phase i cancer trials, Stat Med, vol.27, issue.13, pp.2420-2439, 2008. ,
Methods for dose finding studies in cancer clinical trials: A review and results of a monte carlo study, Statistics in Medicine, vol.10, pp.1647-1664, 1991. ,
Dose-finding designs for HIV studies, Biometrics, vol.57, issue.4, pp.1018-1029, 2001. ,
Continual reassessment method: A practical design for phase 1 clinical trials in cancer, Biometrics, vol.46, issue.1, pp.33-48, 1990. ,
Continual reassessment method: A likelihood approach, Biometrics, vol.52, issue.2, pp.673-684, 1996. ,
Dose finding with longitudinal data: Simpler models, richer outcomes, Statistics in Medicine, vol.34, issue.22, pp.2983-2998, 2015. ,
URL : https://hal.archives-ouvertes.fr/hal-01288874
A comparison of model choices for the continual reassessment method in phase i cancer trials, Statistics in Medicine, vol.28, pp.3012-3028, 2009. ,
Towards new methods for the determination of dose limiting toxicities and the assessment of the recommended dose for further studies of molecularly targeted agents -Dose-limiting toxicity and toxicity assessment recommendation group for early trials of targeted therapies, an European Organisation for Research and Treatment of Cancer-led study, European Journal of Cancer, vol.50, issue.12, pp.2040-2049, 2014. ,
Phase I trials of molecularly targeted agents: Should we pay more attention to late toxicities, Journal of Clinical Oncology, vol.29, issue.13, pp.1728-1735, 2011. ,
Research and development spending to bring a single cancer drug to market and revenues after approval, JAMA Internal Medicine, vol.177, issue.11, pp.1569-1575, 2017. ,
, Medical Genetics Summaries. NCBI Bookshelf, 2015.
Joint latent class models for longitudinal and time-to-event data: A review, Statistical Methods in Medical Research, vol.23, issue.1, pp.74-90, 2014. ,
Improving Oncology Trials Through Adaptive Designs, Applied Clinical Trials, 2015. ,
, , 2016.
, I/II dose-finding design for molecularly targeted agent: Plateau determination using adaptive randomization. Statistical Methods in Medical Research
Joint models for longitudinal and time-to-event data with applications in R, Biostatistics Series, 2012. ,
Order restricted statistical inference, 1988. ,
New paradigm in dose-finding trials: patient-specific dosing and beyond phase i, Clin Cancer Res, vol.11, issue.15, pp.5342-5346, 2005. ,
Interpretation of mixed models and marginal models with cohort attrition due to death and drop-out, 2017. ,
, Statistical Methods in Medical Research, p.096228021772367
New Guidelines to Evaluate the Response to Treatment in Solid Tumors (Ovarian Cancer), Journal of the National Cancer Institute, vol.96, issue.6, pp.487-488, 2004. ,
Definitions for response and progression in ovarian cancer clinical trials incorporating RECIST 1.1 and CA 125 agreed by the Gynecological Cancer Intergroup (GCIG), International journal of gynecological cancer : official journal of the International Gynecological Cancer Society, vol.21, issue.2, pp.419-423, 2011. ,
Methods for the analysis of informatively censored longitudinal data, Statistics in Medicine, vol.11, issue.14, pp.1861-1870, 1992. ,
Response to Imatinib mesylate in chronic myeloid leukemia patients with variant BCR-ABL fusion transcripts, Annals of hematology, vol.89, issue.3, pp.241-247, 2010. ,
Consistency of continual reassessment method under under model misspecification, Biometrika, vol.83, issue.2, pp.395-405, 1996. ,
Accelarated titration designs for phase I clinical trials in oncology, J Nat Can Inst, vol.89, issue.15, pp.1138-1147, 1997. ,
A Bayesian approach to dose-finding studies for cancer therapies: Incorporating later cycles of therapy, Statistics in Medicine, vol.33, issue.15, pp.2665-2680, 2014. ,
, , 2008.
, Shortening the timeline of pediatric phase i trials: the rolling six design, J Clin Oncol, vol.26, issue.2, pp.190-195
Phase 1 trials of molecular targeted therapies: Are we evaluating toxicities properly?, European Journal of Cancer, vol.47, issue.10, pp.1443-1445, 2011. ,
Dose-finding based on efficacy-toxicity trade-offs, Biometrics, vol.60, pp.684-693, 2004. ,
Dose escalation methods in phase i cancer clinical trials, J Natl Cancer Inst, vol.101, issue.10, pp.708-720, 2009. ,
Joint modeling of Longitudinal and Time-toEvent Data: An Overview, Statistica Sinica, vol.14, pp.809-834, 2004. ,
Seamless phase I/II adaptive design for oncology trials of molecularly targeted agents, Journal of biopharmaceutical statistics, vol.25, issue.5, pp.903-920, 2015. ,
, HER2/neu, 2018.
Estimation of clinical trial success rates and related parameters, Biostatistics, pp.1-14, 2018. ,
A joint model for survival and longitudinal data measured with error, Biometrics, vol.53, issue.1, pp.330-339, 1997. ,
Bayesian adaptive dose-escalation designs for simultaneously estimating the optimal and maximum safe dose based on safety and efficacy, Pharmaceutical Statistics, pp.1-18, 2017. ,
, , 2015.
, Bayesian adaptive dose-escalation procedures for binary and continuous responses utilizing a gain function, Pharmaceutical Statistics, vol.14, issue.6, pp.479-487
Bayesian dose finding by jointly modelling toxicity and efficacy as time-to-event outcomes, Journal of the Royal Statistical Society, vol.58, pp.719-736, 2009. ,
Adaptive designs for identifying optimal biological dose for molecularly targeted agents, Clin Trials, vol.11, issue.3, pp.319-327, 2015. ,
An adaptive dose-finding design incorporating both toxicity and efficacy, Statistics in Medicine, vol.25, issue.14, pp.2365-2383, 2006. ,
Overview of phase IV clinical trials for postmarket drug safety surveillance: A status report from the ClinicalTrials.gov registry, BMJ Open, vol.6, issue.11, pp.1-9, 2016. ,
Systematic analysis of circulating soluble angiogenesis-associated proteins in ICON7 identifies Tie2 as a biomarker of vascular progression on bevacizumab, British Journal of Cancer, vol.115, issue.2, pp.228-235, 2016. ,